Watching alerts...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aunt Fannie... HEMP has not been doing anything... have you checked out $STEV?
Jahvik you should check out this recent PR from $STEV:
http://www.prnewswire.com/news-releases/stevia-corp-unveils-30-years-of-ground-breaking-cannabis-research-at-realhempcom-529106221.html
Stevia Corp. Unveils 30 Years of Ground Breaking Cannabis Research at Realhemp.com
INDIANAPOLIS, September 24, 2015 /PRNewswire/ --
Stevia Corp. (OTC: STEV) ("Stevia Corp" or the "Company"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce that its wholly-owned subsidiary, Real Hemp LLC, has unveiled a searchable digital library consisting of more than 30 years of peer reviewed scientific research publications focused on the cannabis plant. Stevia Corp and Real Hemp Advisory Panel member, Dr. Paul Mahlberg, is the author or co-author of each publication included in the library.
The searchable research library contains some of the most important research ever published on the cannabis plant, with specific concentration on glandular trichome development. Dr Mahlberg and his colleague's research has been referenced in thousands of cannabis and hemp articles and publications over the years, including industry leading publications such as High Times Magazine. The research also resulted in some of the most important discoveries about the cannabis plant that are still applied today by some of the most successful cannabis grow operations and industrial hemp farms in the world.
For over three decades, Dr. Mahlberg was known as one of the world's leading researchers of the cannabis plant. Dr. Mahlberg obtained one of only two Drug Enforcement Administration (DEA) Schedule 1 research licenses to pursue studies on cannabis in the United States spanning a period of 33 years from 1970-2003. During that time, he accumulated one of the most extensive seed banks in the world with over 200 strains (including landrace varieties) of cannabis from worldwide sources, which were cultivated in secure greenhouses.
Dr. Mahlberg is a Professor Emeritus of Indiana University and was an active professor in the Botany department of the University until 1994 after which he continued his research on cannabis with visiting faculty and maintained his laboratory until 2003. Dr. Mahlberg received his Ph.D. in Botany from the University of California, Berkley and his M.S. and B.S. degrees in Botany from the University of Wisconsin, Madison.
George Blankenbaker, President of Stevia Corp commented, "We are fortunate to have Dr. Mahlberg on our advisory panel and it is a great honor that he chose our company to make his valuable research available to scientists, growers and consumers. At the time that Dr. Mahlberg was conducting his research, he was a pioneer in a field of study that did not have the full understanding and support of the general public, politicians and other scientists. Now that the true value of the cannabis plant is starting to be known and understood, there is considerable interest by many parties to have access to such research. We are thrilled to be able facilitate the expansion of knowledge of this important plant in support of this important industry."
The research library contains a total of 37 searchable publications that can be viewed at https://www.realhemp.com/mahlberg-cannabis-research/.
Stevia Corp and Real Hemp would like to thank the following public companies for assisting us in publicizing this searchable research library: Cannavest Corp. (CANV:OTCQN), Hemp Inc. (HEMP:PK), India Globalization Capital, Inc. (IGC:NYSE), Totally Hemp Crazy, Inc. (THCZ:PK)
$STEV - Something up their sleeve...
They have teamed with Dr. Paul Mahlberg - he obtained one of only two Drug Enforcement Administration (DEA) Schedule 1 research licenses to pursue studies on cannabis in the United States spanning a period of 33 years from 1970-2003
Stevia Corp. Unveils 30 Years of Ground Breaking Cannabis Research at Realhemp.com
http://www.prnewswire.com/news-releases/stevia-corp-unveils-30-years-of-ground-breaking-cannabis-research-at-realhempcom-529106221.html
INDIANAPOLIS, September 24, 2015 /PRNewswire/ --
Stevia Corp. (OTC: STEV) ("Stevia Corp" or the "Company"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce that its wholly-owned subsidiary, Real Hemp LLC, has unveiled a searchable digital library consisting of more than 30 years of peer reviewed scientific research publications focused on the cannabis plant. Stevia Corp and Real Hemp Advisory Panel member, Dr. Paul Mahlberg, is the author or co-author of each publication included in the library.
The searchable research library contains some of the most important research ever published on the cannabis plant, with specific concentration on glandular trichome development. Dr Mahlberg and his colleague's research has been referenced in thousands of cannabis and hemp articles and publications over the years, including industry leading publications such as High Times Magazine. The research also resulted in some of the most important discoveries about the cannabis plant that are still applied today by some of the most successful cannabis grow operations and industrial hemp farms in the world.
For over three decades, Dr. Mahlberg was known as one of the world's leading researchers of the cannabis plant. Dr. Mahlberg obtained one of only two Drug Enforcement Administration (DEA) Schedule 1 research licenses to pursue studies on cannabis in the United States spanning a period of 33 years from 1970-2003. During that time, he accumulated one of the most extensive seed banks in the world with over 200 strains (including landrace varieties) of cannabis from worldwide sources, which were cultivated in secure greenhouses.
Dr. Mahlberg is a Professor Emeritus of Indiana University and was an active professor in the Botany department of the University until 1994 after which he continued his research on cannabis with visiting faculty and maintained his laboratory until 2003. Dr. Mahlberg received his Ph.D. in Botany from the University of California, Berkley and his M.S. and B.S. degrees in Botany from the University of Wisconsin, Madison.
George Blankenbaker, President of Stevia Corp commented, "We are fortunate to have Dr. Mahlberg on our advisory panel and it is a great honor that he chose our company to make his valuable research available to scientists, growers and consumers. At the time that Dr. Mahlberg was conducting his research, he was a pioneer in a field of study that did not have the full understanding and support of the general public, politicians and other scientists. Now that the true value of the cannabis plant is starting to be known and understood, there is considerable interest by many parties to have access to such research. We are thrilled to be able facilitate the expansion of knowledge of this important plant in support of this important industry."
The research library contains a total of 37 searchable publications that can be viewed at https://www.realhemp.com/mahlberg-cannabis-research/.
Stevia Corp and Real Hemp would like to thank the following public companies for assisting us in publicizing this searchable research library: Cannavest Corp. (CANV:OTCQN), Hemp Inc. (HEMP:PK), India Globalization Capital, Inc. (IGC:NYSE), Totally Hemp Crazy, Inc. (THCZ:PK)
HEMP and STEV working together? I seen news show up under this ticker... any ideas?
Why was STEV PR listed under this company today? Find that interesting...
So I see that STEV came up on CANV's PR radar today - whats up with that?
First of all... this article is way over used to depict the market downturn. It does not offer any evidence of lost money.
Yes there was a bubble last year, yes people lost money, but that was only because they did not research what they were buying. Of course, shady shells rise up in times like this and especially when there is a market rising that has been non-existent for over 50 years.
Stevia Corp. still need to prove it's position to me and the financials will be the start of that transparency. Meaning that, just because financials are released I will stick around. It will be a measure of whether or not to stay here. It should show growth and not back pedal.
The biggest issue is the fact I don't know what they do in Asia. Neither do you. Maybe if the company can make Realhemp turn into something then their Asian partners will help the company grow through investments... it does happen believe it or not. See this article:
http://www.wsj.com/articles/why-asias-tech-giants-are-investing-in-u-s-startups-1426208938
While Stevia Corp is not a Tech Start up I would position the company in the bottom 3 sectors depicted in the article.
Also, let's keep in mind that investments are made to help public businesses grow and this is something that will take time. If you prefer to make money in the short term then you need to become a trader. Or if you are trying to protect people from making bad decisions... become a priest.
Truthfully speaking the markets need both (long term investors and short term traders) in order to work and that's ok.
Back to that horrible article head line... "Marijuana Investors Lost $23.3 Billion in Penny Stocks Last Year"
It could have also been said that "Marijuana Traders Gained Billions in Penny Stocks Last Year"
Next year the title could be "Early Marijuana Investors Gained Billions from public start ups"
My point is that the article is skewed, your rants are unjustified simply posting a link to, as I mentioned, horrible journalism and last but not least the industry is just starting.
By the way - love your quote in your profile that completely contradicts your stance of even having an opinion:
We cling to our own point of view, as though everything depended on it. Yet our opinions have no permanence; like autumn and winter, they gradually pass away.
Zhuangzi
Take note from your own gospel...
I'm sure the next frenzy will blow people away... I have been watching for a while. The company has had it's "pops" however the trend in stock price has been downward over time.
That's about the only thing I will read on these type of charts... One thing I am and have been waiting for are the financials. Should they prove to be realistic (forget over the moon speculation) I am ready to invest.
I said in the past, I won't pull my wallet out until then. So I assume there are a lot of people ready to throw money at this at the right time.
So I am supporting $STEV in that manner for the moment.
I'm curious how many side-liners are watching this one...
They know we are waiting... I know I am waiting...
Needs Fina to pull my wallet out (or put it back)
Looks as if AIS Aqua Shrimp will be buying the stevia fish feed from George... check out the site for the company here:
http://aisaquashrimp.com/
Here is the project page here:
http://icrowdnewswire.com/2015/08/06/ais-aqua-shrimp-the-colombia-next-generation-shrimp-project/
Now Stevia Corp. has my attention... now if they can release some damn financials to prove to me I should actually invest.
Good weekend to all
Take a look at this! The Colombia Next Generation Shrimp Project
George is listed at the very bottom of this article as a contact person - looks like this might actually come alive! Probably will sell his Stevia Fish Feed into this project.
http://icrowdnewswire.com/2015/08/06/ais-aqua-shrimp-the-colombia-next-generation-shrimp-project/
iCrowdNewswire - Aug 6, 2015
COMPANY OVERVIEW
Exceptional Market Opportunity. Changing dynamics in the global shrimp market today have created a “perfect” storm” for a new generation of investment in shrimp aquaculture production:
Asian shrimp aquaculture production was down by 19% in 2014 due to EMS disease. With Asian production based largely on highly dense concentrations of ponds in marine environments with poor water quality, Asian producers will remain extremely vulnerable to continued risks of disease and pressure to use antibiotics.
Chinese domestic demand for shrimp is growing, causing China to increase imports of shrimp to make up for shortfalls in domestic production, and providing a price support for new supply entering the global shrimp market. This trend is expected to continue for next three to five years.
Shrimp exports to China are therefore increasing, while US imports remains stable.Shrimp exports from Ecuador to Asia, for example, increased by 73% in 2013 and 61% in 2014 to meet expanding market demand in China.In 2014, China replaced the US as Ecuador’s biggest customer.
Demand for the highest margin, cooked product in Europe continues at consistently high levels, despite periods of financial instability, and is expected to increase as the EU economy accelerates recovery.
Recent revelations about abusive labor practices have discredited many producers in the Asian shrimp industry, highlighting their reliance on deeply entrenched illegal labor practices and adding to the current set of food safety and environmental issues of concern to EU and US buyers and consumers.[1] . For example, Thailand was downgraded to a Tier 3 ranking in the US State Department’s 2014 Trafficking in Persons (TIP) Report, the most negative classification.[2]
Strong Value Proposition.The Colombia Next Generation Shrimp Project will becash flow positive in the first year, based on:
Favorable market prices, due to current market dynamics as described above.
High volume:Capacity for three production cycles per year, based on a growth cycle of 90-120 days in a disease free zone.
High quality:Integrated, modern hatchery, production and value added processing infrastructure and assets ready for operation.
Immediate market access: AIS Aqua’s (AIS) established relationships with its customer base and its reputation for delivery of safe, high quality shrimp, fish and seafood products, provides immediate market access. Since 1996, AIS has been a principal vendor to Darden Restaurants, which includes Olive Garden and Longhorn Restaurants, and has successfully implemented program sales & distribution plans and vendor managed inventory (VMI) systems with large buyers, such as Red Lobster Restaurants.
Unique logistics advantages: The location of the processing facility within the Cartagena Free Trade Zone allows the project to import production and processing equipment duty free; its proximity to US markets offers cost advantages for shipping to the US, European, South American, and Mexican markets; and, its proximity to the Panama Canal provides direct access to the Chinese market.
Qualified local management team and experienced local labor force.AIS explicitly retained qualified local management and labor to avoid the loss of institutional knowledge and to maintain the commitment of the local communities to the successful operations of the farm, which has been operating the farm since 1983 and serving as an important economic asset for the three adjacent communities.
Low-risk 5-year lease/purchase agreement allows for immediate startup of operations without additional capital investment, ensuring production, profitability and payment to investors before the principal option to buy is exercised.
Highly Competitive Product: The Colombia Next Generation Shrimp Project will have the capacity to rapidly produce a high volume, high quality, disease-free product that can take advantage of favorable market conditions, based on the following competitive factors:
Production in Caribbean waters free of disease, located next to a national park and protected by natural zoning separators and mangroves.
Low-density stocking model that reduces stress on animals, resulting in consistent excellent survival rates.
Hatchery sited separately from the production area, which ensures bio-secure production of post larvae.
Proven advanced natural genetic selection process for Specific Pathogen-Free (SPF) brood stock, selecting for shrimp health, vitality and growth.
Introduction of steviol glycosides in feed that reduces stress and improves survivability by fostering healthy digestion and increasing feed conversion through better nutritional uptake, resulting in increased immunity to disease, faster growth, and higher yields.
Ecosystem benefits.The extensive coastal mangroves bordering the production area provide essential ecosystem benefits to shrimp farming, by serving as a buffer and filtration mechanism for the estuarine system that passes fresh water through the shrimp farm. Protecting and maintaining this estuarine system will also allow for poly-culture of “salt tolerant” tilapia, which is in high demand in the USA.
Social compact with local rural communities to provide much needed employment, road improvements, health assistance, and sports opportunities, with an emphasis on women and youth.
Advanced value-added processing equipment and technology able to comply with Global HACCP standards and strict EU sanitary requirements.
Food safety record: Managing Director Andrew Kaelin is a globally recognized expert in food safety, and has received a number of awards, including Darden Restaurants’ “Award for Food and Beverage Quality and Safety” for prevention of antibiotic use and extension of shelf life for seafood product from China.
Quality control: Based on the phase one raise already completed, the project will exercise its option to buy the processing facility for US$1.00 before the option to buy the farm is exercised, guaranteeing total control over quality assurance.
Experienced Professional Team. AIS Aqua Shrimp is a division of AIS Aqua Foods (AIS), whose competitive advantages include:
Over 55 years experience in the international seafood and aquaculture business, including shrimp farming in Central America, and scallop, shrimp and tilapia production in China, Peru and Colombia, serving major seafood buyers in the US market.
AIS Managing Director Andrew Kaelin who has been a consultant to the World Bank since 1989, analyzing more then US$700 million of fisheries and aquaculture loans, and is a globally recognized seafood expert who continues to speak and serve as panel member at annual seafood conferences.
Founding Member and past sponsor of the Global Aquaculture Alliance (GAA) and actively involved in the National Fisheries Institute (NFI) and a frequent advisor to the International Coalition of Fisheries Associations (ICFA).
Project implementer for global fisheries sustainability project with funding from Allfish (World Bank), and GEF (Global Environmental Fund).
Strategic partnership with Stevia Corp (a publically traded company, STEV), who has developed proprietary glycoside formulas, protocols, probiotics and enzymes for shrimp feed.
Operational Assets. The Colombian Next Generation Shrimp Project comprises:
Production Area: 81 grow-out ponds on 680 hectares, with and estimated production of more then 8 million pounds annually, employing approximately 250 workers, the majority with prior shrimp farming experience.
Hatchery:Will produce post-larvae for the grow-out ponds but initially SPF bio-secure post-larvae will be purchased to stock the grow-out ponds.
Processing Plant:The seafood processing facility in Cartagena’s Free Trade Zone will have the capability of processing and shipping the shrimp harvested from the grow-out ponds, employing approximately 300 worker (mostly woman) once the shrimp farm is in full production.
Contact Information:
Anwar Kaelin
George Blankenbaker (The man himself)
Andrew Kaelin (Stevia Corp Advisor)
Santiago Sierra
Drew Blankenbaker - Farmer, Lifeline Produce
https://www.linkedin.com/pub/steve-lehrer/0/15b/8b8
Montana Medical Marijuana Act, Mont. Code Ann. §§ 50-46-1 to 50-46-2 (2007) is effective...
Could the Blankenbaker family be connected is such a coincidental way - Sure seems interesting hmmmmm.....
Ross Jaax is a real person...
http://www.findagrave.com/cgi-bin/fg.cgi?page=gr&GRid=40153639
Link above is the obituary of Ross's mother - states that Ross Jaax is married to (or was) Aryany of Saigon, Vietnam
Just tossing this in with the DD - not that it means any thing too concrete at this point.
Woooooo! Sweet Jesus!
Ok. This last month has been good (stability and interest). Let's see if they file on time or go to the Pinks. Otherwise, I am out of here.
Good luck to those longs currently in.
Football season ahead... Habanero Hellfire Chili
http://m.allrecipes.com/recipe/25370/habanero-hellfire-chili/?mxt=t06rda
Patriots or Steelers? Go!
Feelings on Jimmy Garoppolo entering Second Preseason With Patriots. I for one am excited about this!
Good find. Let's see if he lives up to all this. Thanks for sharing Burton.
Hey - you showed back up. You going to bet on this horse again? Just waiting for fins - if it sinks to pinks no way. Come on management... we have money ready!
We won't truly know that until the end of the year... unless they already stated it which I did not catch.
You are not getting fins today... The agronomic and economic potential of industrial hemp, as well as the legal issues surrounding its production, will be the focus of a Purdue Extension field day Aug. 25.
If they are doing anything today it is visiting that demo and site visit. No complaints here.
http://www.purdue.edu/newsroom/releases/2015/Q3/industrial-hemp-production-focus-of-purdue-field-day.html
You seem to be the excited one of the bunch (lot's of manic comments). However, I see you have been investing for some time now. So I guess the comments are warranted.
Of course the stock is resting for now after the rise it had, but this might be short lived - waiting for the next pull back. I may miss the train, but still not taking a position position yet.
Don't read the charts... read between the lines. Those patents for Aspirin, Naproxen, Acetaminophen and Ibuprofen are monumental. I hope for their sake they get them wrapped up. It could be one of the biggest shockers the OTC (both in the pharmacy aisle and the market here) will see in a long time.
Lots of companies are looked at like jokes as I said. They successfully pull this off and they will give everyone a black eye. What a sight to see if it actually occurs.
Why did Panzer start rallying for SIPC? I see he moved over to that board. That company doesn't have anything going for it. Just a shame to see him leave the board - he seemed to keep everyone here calm (joking board seems calmer now)
Finally turning a corner. It had my curiosity. Now it has my attention - it's crazy but I won't take a position just yet. When it breaks .08 is when I see the fun you call volume stepping up. Right now it's a game to get a few 100K.
I'll help slap when the times ready. I'll never reveal a my personal target but it's not close to this and the fake excitement being generated.
The patents are really the play here (we need to see fins for confirmation of growth in Asia) - will make both longs rich and the company have some change to invest in growth. An opportunity to really grow and hire key people. If they are able to secure the patents past being provisional - then we have a real stallion here. Screw unicorns. I don't believe in fairy tales and this market is full of them.